Browse the evidence

SCD1 is a key enzyme that regulates energy homeostasis and various physiological processes.

Understanding SCD1's role can help in targeting metabolic diseases.

Aberrant activation of SCD1 contributes to obesity, non-alcoholic fatty liver, diabetes, and cancer.

Targeting SCD1 may help in managing these metabolic diseases.

Psychotropic drug-related weight gain (PDWG) is highly associated with non-initiation, discontinuation, and dissatisfaction with psychiatric drugs.

Practitioners should be aware of the impact of PDWG on patient adherence to psychiatric medications.

Significant disproportionality for semaglutide remained in patients with coreported use of antidepressants and benzodiazepines.

Clinicians should consider the interaction of semaglutide with antidepressants and benzodiazepines when assessing risk.

To achieve nondominance, the annual price of semaglutide would need to be reduced from $13,618 to $3,591.

This suggests that pricing strategies for semaglutide could significantly impact its adoption in clinical practice.

The implementation of MTMs could potentially lead to net cost savings of $13.6 billion annually from a health care perspective.

Expanding coverage for MTMs could be a financially beneficial policy for healthcare systems.

The evidence for the benefits of power training on physical function and self-reported function was rated as low-certainty.

Practitioners should be aware of the limitations in the evidence when recommending power training.

GLP-1 analogs may interact with estrogens.

Consideration of estrogen interactions may be important in treatment plans involving GLP-1 analogs.

A personalized diet targeting a reduction in postprandial glycemic response did not result in greater weight loss compared to a low-fat diet at 6 months.

Practitioners may consider that personalized diets based on PPGR may not provide superior weight loss outcomes compared to standard low-fat diets.

Tirzepatide improved glucose control in overweight and obese patients with type 1 diabetes.

Tirzepatide may be beneficial for improving glycemic control in this demographic.

69,213,936 prescriptions for obesity medications (OMDs) were dispensed in the US from July 2017 to February 2024, with a mean annual growth rate of 5.3%.

Healthcare providers should be aware of the increasing trend in OMD prescriptions.

The severity of hypothalamic inflammation and gliosis is related to comorbid conditions such as glucose intolerance and insulin resistance.

Understanding these relationships can help in targeting treatment for obesity-related comorbidities.

Pre-operative semaglutide use within 10 days of elective surgical procedures was independently associated with increased risk of residual gastric content on pre-operative gastric ultrasound assessment.

Practitioners should consider the timing of semaglutide administration in relation to elective surgeries to mitigate the risk of increased residual gastric content.

Increased residual gastric content was found in 40% of patients in the semaglutide group compared to 3% in the non-semaglutide group.

The significant difference in residual gastric content suggests that semaglutide may pose a risk during surgery, warranting careful assessment.

Gastrointestinal adverse events were common with maridebart cafraglutide, although less frequent with dose escalation and a lower starting dose.

Clinicians should monitor for gastrointestinal side effects when prescribing maridebart cafraglutide.

There is no consensus on the best nutritional strategy or ideal dietary prescription for the management of Type 2 Diabetes Mellitus (T2DM).

Practitioners should consider individual variability when recommending dietary strategies for T2DM.

Higher variability of body mass index (BMI) is associated with a significantly increased risk of all-cause mortality, cardiovascular deaths, and cardiovascular events in individuals with type 2 diabetes in the control group.

Practitioners should monitor BMI variability in patients with type 2 diabetes as it may indicate higher risks for adverse cardiovascular outcomes.

Higher variability of waist circumference (WC) is associated with increased risks of cardiovascular outcomes and death in the control group.

Monitoring waist circumference variability may be important for assessing cardiovascular risk in patients with type 2 diabetes.

In rheumatoid arthritis (RA), improved disease activity was reported with GLP-1 receptor agonists.

GLP-1 receptor agonists may be beneficial for improving disease activity in RA patients.

The restore diet reduced gut microbiome diversity but enhanced the persistence of L. reuteri strain.

Practitioners should note that while diversity may decrease, specific beneficial strains can be enhanced through targeted dietary interventions.

GLP-1 receptor agonist use was associated with a higher risk of discontinuation of endoscopy compared to SGLT-2 inhibitors.

Practitioners should be aware of the increased risk of endoscopy discontinuation when using GLP-1 receptor agonists.

Adverse measures of body composition in individuals of any weight can also confer increased breast cancer risk.

Practitioners should assess body composition in addition to BMI when evaluating breast cancer risk.

Insulin sensitizers such as PPARγ (pioglitazone) and pan-PPARs agonists (lanifibranor) have shown beneficial effects on both NASH and liver fibrosis.

Consider insulin sensitizers as part of the treatment plan for NASH and liver fibrosis.

Endothelial dysfunction is associated with hypercholesterolemia and obesity.

Understanding endothelial dysfunction can help in the treatment of CVD risk factors.